Kanghong Pharmaceutical and Vanotech Ltd. today announced the successful completion of a Phase 2b clinical trial evaluating KH607 in adults with major depressive disorder (MDD). HIGHLIGHTS Phase 2b ...
Among people with major depressive disorder, treatment with semaglutide reduces the perceived cost of effort and improves motivation.
Ketamine has been hailed as a fast-acting, effective treatment for major depression. But new research questions whether the ...
Phase 2b Trial Met Primary Endpoint, Demonstrating Strong Efficacy and Favorable Safety Profile; Phase 3 PlannedCHENGDU, China and ROCKAWAY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Kanghong Pharmaceuti ...
A new meta-analysis shows meaningful differences among FDA-approved antipsychotic adjuncts for MDD, with lumateperone showing the strongest efficacy and aripiprazole the best overall acceptability.
A new study uses real-time fMRI neurofeedback to help depression patients reduce rumination by training specific brain ...
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in ...
Summary: A Phase 2 randomized clinical trial demonstrates that a single 25 mg dose of psilocybin, combined with psychotherapeutic support, provides rapid, statistically significant, and clinically ...
Detailed price information for Definium Therapeutics Inc (DFTX-Q) from The Globe and Mail including charting and trades.
Major Depressive Disorder (MDD) is far from a cookie-cutter diagnosis. Different patients report suffering from different subsets of symptoms, yet most are ultimately prescribed the same first-line ...
Significant genetic correlations were found between pediatric neuropsychiatric conditions and various ocular disorders.
Antonio Guterres Sakataren majalisar Dimkin Duniya, a jiya Laraba, ya ce yankin Sahel na bukatar jin kai ganin ta yada ya ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results